Steven Tong
@steventong.bsky.social
Infectious diseases, clinical trials, staphylococcus and streptococcus. Reader and runner. Go Hawks!
This course will be great! In Malta too - still warm in November. COI: I'm one of the conveners. Join us!
ESCMID@escmid.bsky.social · 2w ago💡 Take your clinical trial from concept to completion. Join this onsite course and learn how to design, conduct and report a clinical trial through expert-led sessions and workshops covering every stage of the clinical trial journey. Register today: https://ow.ly/lStL50Zrgqa #IDSky #clinmicro
The SNAP Trial Exemplifies What EBM Should Look Like: www.sensible-med.com/p/the-snap-t... #IDSky
The SNAP Trial Exemplifies What EBM Should Look Like
It's always worth showing properly designed and conducted trials--though it's bad for pageviews. Nonetheless, SNAP authors show the way to answering questions in biomedicine
sensible-med.com
The SNAP trial domain on cefazolin vs cloxacillin for MSSA bacteremia is finally published! www.nejm.org/doi/full/10.... Cefazolin is already the new standard! #IDsky #AMSsky
A landmark international clinical trial (SNAP Trial) has identified the optimal antibiotics for golden staph bloodstream infections, a breakthrough that is set to reshape treatment for the life-threatening condition. https://bit.ly/44eY8Kg
Global clinical trial reveals safest, most effective antibiotics for golden staph bloodstream infections
A landmark international clinical trial has identified the optimal antibiotics for golden staph bloodstream infections, a breakthrough that is set to reshape treatment for the life-threatening condition.
doherty.edu.au
In the SNAP trial, cefazolin was noninferior to flucloxacillin or cloxacillin with respect to 90-day mortality in patients with methicillin-susceptible Staphylococcus aureus bacteremia and had fewer nephrotoxic effects. Read the full trial results: https://nej.md/4vL0M6m
🔥Just published 🔥NEJM SNAP RCT In patients with MSSA bacteremia, cefazolin was noninferior to flucloxacillin or cloxacillin with respect to 90-day mortality and was associated with a lower incidence of acute kidney injury. #idsky www.nejm.org/doi/full/10....
Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia | NEJM
Staphylococcus aureus bacteremia is associated with high mortality. Whether cefazolin or an antistaphylococcal penicillin should be preferred for the treatment of methicillin-susceptible S. aureus ...
nejm.org
Excited 1st SNAP result out @thelancet.com PSSA: Fluclox v BenPen thelancet.com/journals/lancet/article/PIIS0140-6736(26)00761-0/fulltext @nejm.org MSSA: Fluclox v Cefazolin nejm.org/doi/full/10.1056/NEJMoa2506905 Should change practice globally Privilege to help deliver trial with fantastic team
helancet.com
Great post @apsmunro.bsky.social! Doing more is such a natural reaction. But even 'benign' interventions may likely be harmful when tested properly. I'm yet to know of a trial for sepsis where adding antibiotics has been beneficial (outside of TB where we do it to prevent emergence of resistance).
Alasdair Munro@apsmunro.bsky.social · 2mo agoMy new post looks at two antimicrobials which have been routinely used and even recommended in guidelines despite a lack of RCT evidence In the last few weeks they’ve both been shown to have no benefit, and worse, high probability of harm - killing patients A lesson we keep failing to learn
Honored to contribute to this peer-reviewed commentary in CMI Communications alongside an incredible panel of ID physicians and clinical trialists discussing some of the top infectious diseases papers of 2025. #idsky www.cmi-comms.org/article/S295...
This is a really helpful graphic summary of the Andes virus outbreak. #IDSky
Ian M. Mackay, PhD (he/him) 🦠🤧🧬📑🦟🧀@mackayim.bsky.social · 3mo agoVersion 9. New Canadian case (seen one link saying moved to hospital 14th, so presumably onset date), confirmed 14th. Fixed "2">>"3" April for Case 1. We're past the 42nd day - 6-week - of incubation since Case 1 onset. Can be as long as 8-weeks in a small percentage. Still all boat-related
ESCMID 2026 highlights Dalbavancin PK (DOTS‑PK) – Two doses may not be enough High protein binding and wide inter‑patient variability: 1/3 patients may be sub‑therapeutic by day 22 Bottom line: Consider monitoring levels or adding a third dose in complex infections clarityinitiative.org/home
Clarity Initiative
Clarity Initiative offers clinical literature appraisal and research education in infectious diseases, enhancing knowledge through courses and resources.
clarityinitiative.org
So good. Have spent years fighting this fight, with hand tied behind my back by lack of great evidence. This study is going to get quoted and cited in microbiology MDTs the world over +++ #IDSky #ClinMicro #AMR
Steven Tong@steventong.bsky.social · 3mo agoESCMID 2026 highlights COBRA Trial – One day is enough Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days. Bottom line: Antibiotic durations can safely be much shorter once source control is achieved. #IDSky clarityinitiative.org/escmid-2026-...
ESCMID 2026 highlights COBRA Trial – One day is enough Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days. Bottom line: Antibiotic durations can safely be much shorter once source control is achieved. #IDSky clarityinitiative.org/escmid-2026-...
Clarity Initiative
Clinical Literature Appraisal and Research education in InfecTious diseases
clarityinitiative.org
Highlights from ESCMID Global 2026? @gurujosh.bsky.social asked CLARITY faculty: @angelahuttner.bsky.social @erinmccreary.bsky.social @marcbonten.bsky.social @seanong.bsky.social @ashabowen.bsky.social and others (not on BlueSky). #IDSky clarityinitiative.org/escmid-2026-... Any that we missed?
Clarity Initiative
Clinical Literature Appraisal and Research education in InfecTious diseases
clarityinitiative.org
Our collaboration episode with Breakpoints covering the trials from the ESCMID Global session 'The trial run' is out now! share.transistor.fm/s/e2a9aee4 🎙️✨ @erinmccreary.bsky.social @gurujosh.bsky.social @jesusrbano.bsky.social #IDSky #clinmicro
Communicable E52: ESCMID Global Trials, PETER PEN and ASTARTE | Communicable | Episode 52
In this collaborative episode of Breakpoints and Communicable, the hosts revisit the “trial run” session from ESCMID Global, a format designed to facilitate critical discussion of major infectious dis...
share.transistor.fm
Society of Infectious Diseases Pharmacists - SIDP@sidpharm.bsky.social · 3mo agoThe Society of Infectious Diseases Pharmacists and ESCMID are excited to release a new Breakpoints episode: ESCMID Global Trials: PETER PEN and ASTARTE Check it out!
Long awaited! 🆕💥🟢REMAP-CAP For critically and noncritically ill hospitalized patients with COVID-19, ivermectin was unlikely to improve the primary composite outcome of organ support-free days and hospital survival #idsky journals.lww.com/ccmjournal/f...
Ivermectin for Critically and Noncritically Ill... : Critical Care Medicine
between June 11, 2021, and September 9, 2022. Patients: Critically and noncritically ill patients. Interventions: Randomized to ivermectin or no ivermectin (control). Measurements and Main Resu...
journals.lww.com
We looked at empiric B-lactam antibiotics in MRSA bacteraemia and BC persistence and AKI, using CAMERA2 dataset. Groups: none, early (only empiric B-lactam), late (only after trial enrolment), throughout (empiric and after enrolment). #IDSky www.clinicalmicrobiologyandinfection.org/article/S119...
Time for societies to incorporate humility of uncertainty into guidelines Evidence Over Eminence: Rethinking Specialty Guidelines Amid the ATS-IDSA Debate academic.oup.com/cid/article/...
Evidence Over Eminence: Rethinking Specialty Guidelines Amid the ATS-IDSA Debate
Brad Spellberg, MD, Bassam Ghanem, PharmD MS BCIDP, Miguel Morante-Ruiz, MD, Émilie Bortolussi-Courval, RN PhD, Anil N Makam, MD MAS, Zeynep Ergenc, MD, Ni
academic.oup.com
🔥 Late Breakers SNAP platform RCT| Adjunctive Clindamycin in S.aureus bacteraemia ❌ No mortality benefit 90d mortality:16.9% vs 15.2% aOR 1.16 (CrI cross 1) 📊PPSup(~7%)→Futility threshold reached ⚠️ICU subgp:numerically worse with clinda ⚖️CDAD:no # (~2%)😯 #ESCMIDGlobal2026 #idsky
📣 New CLARITY articles by Erin McCreary, PharmD & Ahmad Mourad are out to help us understand the GAMECHANGER trial & #cefiderocol The first notes a mortality signal among metallo-β-lactamase–producing infections... #IDSky #clinmicro https://ow.ly/GAqx50Yq6uh
How do we win? The GAME CHANGER trial
ow.ly
And @gurujosh.bsky.social and I just recorded a podcast with Scott Berry for 'In the Interim'. We discuss the SNAP journey so far. www.berryconsultants.com/resources/po.... Episode should drop in 2-3 weeks. Will post again when it does. @thedohertyinst.bsky.social #IDSky
In the Interim... | A Podcast by Berry Consultants
A podcast on statistical science and clinical trials.
berryconsultants.com
Steven Tong@steventong.bsky.social · 5mo agoJust woke up and checked emails to see that 8 new participants recruited to #SNAP_Trial in the past 8 hours! While a number of domains have closed (PSSA, MSSA, adjunctive clindamycin) we continue to recruit to other domains. Beyond 5,800 total participants now. @gurujosh.bsky.social
Just woke up and checked emails to see that 8 new participants recruited to #SNAP_Trial in the past 8 hours! While a number of domains have closed (PSSA, MSSA, adjunctive clindamycin) we continue to recruit to other domains. Beyond 5,800 total participants now. @gurujosh.bsky.social
We were absolutely the beneficiaries of your visit @angelahuttner.bsky.social! We learnt so much about scientific communication and publishing, gender equity in medicine and science, and UTIs! (each was the focus of a talk / discussion Angela led). #IDSky
Angela Huttner @angelahuttner.bsky.social · 5mo agoA big thank you to @steventong.bsky.social, @trubianojason.bsky.social & the hugely impressive team at @thedohertyinst.bsky.social for a morning of fascinating research presentations & an afternoon/evening of thoughtful discussions. Open-minded, creative ID thinkers to be inspired by. 🤩🤩🤩 #IDSky
With ESCMID Global quickly approaching! To help you spread the word and get involved, check out ESCMID Global 2026 Promotional Toolkit The official hashtag for the congress this year is #ESCMIDGlobal2026 on all social media channels. #IDSky www.escmid.org/congress-eve...
Promotional Toolkit
ESCMID Global (formerly ECCMID): an annual congress bringing together experts and specialists in Clinical Microbiology and Infectious Diseases.
escmid.org
My top 10 ID papers for 2025. Full citations and descriptions available at clarityinitiative.org/hot-takes Also see/hear our Communicable podcast episode on this at communicable.transistor.fm/episodes/com... What were your top 10? Any thoughts about what I missed welcome! #IDSky #Top10papers
Medical research spending has a positive return on investment; for every $ invested there's an estimated $4 return. Beyond economics, delays hold up medical innovations Australians deserve better If you agree, please sign the petition to let #auspol leaders know why medical research matters #NHMRC
Dr Monique Ryan@mon4kooyong.bsky.social · 6mo agoRight now, the Government is starving medical research of full funding, even as it claims that science and research are national priorities. If our leaders truly value science as much as they say, then they must back their words with action—and fund it properly. Join the campaign!
🎙️ Just published Communicable E45: Top infectious diseases papers in 2025 Hosted by Josh Davis & Emily McDonald w/ invited guest Steven Tong Listen on #Communicable: https://share.transistor.fm/s/9e626f2a #IDSky #clinmicro
Communicable | Communicable Episode 45: Top infectious diseases papers in 2025
In this episode of Communicable, Josh Davis (Newcastle, Australia) and Emily McDonald (Montreal, Canada), plus invited guest, Steven Tong (Melbourne, Australia)—all practicing physicians and clinical trialists— assemble to discuss some of their ‘top infectious diseases papers published in 2025’....
share.transistor.fm
📣 New #Communicable drops Mon 26 Jan! In our last episode, we brought you some favorite #clinmicro papers of 2025. We continue this thread in our next episode with top ID papers of 2025, picked by our editors, Josh Davis & Emily McDonald and guest, Steven Tong. ⭐ Tune in Monday🎙️ #IDSky
💊Drug Hypesensitivity Symposium 2026 - #DHS2026 Registrations are now open for our amazing 3-day #drugallergy & #antibioticallergy program in Melbourne 23-25th October 2026. Stellar international🌏speaker lineup. @allergy-eaaci.bsky.social @thedohertyinst.bsky.social ➡️https://dhs2026.org/
